NewsBenzingaAlumis New Phase 3 ONWARD Data Show Envudeucitinib Improved Scalp, Itch And Quality Of Life In Psoriasis, Building On 54% PASI 100 At Week 48; NDA On Track For 4Q 2026 Alumis New Phase 3 ONWARD Data Show Envudeucitinib Improved Scalp, Itch And Quality Of Life In Psoriasis, Building On 54% PASI 100 At Week 48; NDA On Track For 4Q 2026 Benzinga 2026.10.09 08:20 (GMT+0) Open on Benzinga Other news Hearing Nvidia Chair Says Jensen Huang Not Coming Back Here’s How Much You Would Have Made Owning KLA Stock In The Last 20 Years Fed Minutes: 'Almost All' Officials See More Hikes, and AI Debt Is Now on the Radar Freedom Broker Maintains Buy on Euroseas, Raises Price Target to $96 Freedom Broker Maintains Buy on JD.com, Lowers Price Target to $40 Freedom Broker Maintains Buy on i-80 Gold, Lowers Price Target to $2.8